Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status
- Citation:
- Ann Oncol vol 25 (suppl 4)
- Meeting Instance:
- ESMO 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Published Only
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2247
- Pharmas:
- Grants:
- Corr. Author:
- Edith A. Perez
- Authors:
- Edith A. Perez Eileen Holmes José Baselga Evandro de Azambuja Amylou C. Dueck Giuseppe Viale Jo Anne Zujewski Aron Goldhirsch Rocco Crescenzo Kathleen I. Pritchard Antonio C. Wolff Christian Jackisch Istvan Lang Michael Untch Ian Smith Frances Boyle Binghe Xu Henry Gomez Richard D. Gelber Martine Piccart-Gebhart
- Networks:
- LAPS-MD017, LAPS-MN026, LAPS-NY016, PR028
- Study
- NCCTG-N063D
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: